Merck Phase 2b/3 MALBEC Trial for nAMD
Key Questions
What is the MALBEC trial?
The MALBEC trial is Merck's pivotal Phase 2b/3 study evaluating MK-8748 (Tiespectus), a bispecific Tie2 agonist/VEGF inhibitor, for neovascular age-related macular degeneration (nAMD). It compares the therapy against aflibercept dosed every 8 weeks, aiming for a more durable treatment following the RIOJA study.
What is MK-8748 (Tiespectus)?
MK-8748, also known as Tiespectus, is an investigational bispecific antibody that acts as a Tie2 agonist and VEGF inhibitor. It is being developed by Merck to provide longer-lasting therapy for nAMD patients.
What is the current status of the MALBEC trial?
Merck has announced the initiation of the pivotal Phase 2b/3 MALBEC trial. The study is advancing as part of efforts to develop a durable nAMD therapy.
Merck advancing pivotal Phase 2b/3 MALBEC for MK-8748 (Tiespectus), bispecific Tie2/VEGF vs aflibercept q8w, targeting durable nAMD therapy post-RIOJA.